Thread by @Biotech2k1

Looking at my Synthetic Biology Companies:

The synthetic biology space is all about creating new biology. This is mostly around engineering yeast or bacteria to become tiny factories. This offers a sustainable resource for rare products.

I have:

$DNA 1.38%
$TWST 1.38%
$ARMS 2.06%
$CDXS .69%

This theme makes up 5.51% of my portfolio.

$DNA is the fan favorite for this space, but it also prices in a huge amount of success already. They focus on engineering microbes to be tiny factories to product products. They also engineer microbes for commercial products like probiotics.

$TWST is the DNA company. They engineer, sequence, and create DNA for all kinds of applications including $DNA. They have multiple business segments for DNA manufacturing, sequencing, clinical development and data storage. DNA as a data storage medium sounds so Scifi.

$AMRS is another company working on turning microbes into factories to produce products. They already have several commercial products with strong sales. Their management is not the best, but they are way ahead of $DNA and at a fraction of it value.

$CDXS is the enzyme company. They design and develop enzymes for use in drug development. They make DNA and RNA polymerases. They are making the key enzyme in the new Pfizer Covid pill. They can reduce time and costs significantly with their enzymes.

This is another new space for me. Most of my positions are still very small as I try to build them into any sell offs. I have picked my top 3 I would rally around if I had to triage into a bad market.

I think I would cut $AMRS even at a small loss because it is the weakest managed of the 3 companies. Its clearly my underdog play.

I think there is a clear need in this ever growing world to find more sustainable ways to produce key components.